Cadent Therapeutics announced the U.S. FDA has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for CAD-1883 in patients with Spinocerebellar Ataxia.  The Phase 2 trial is a multicenter, randomized, placebo-controlled study...